Immune reconstitution in chronic lymphocytic leukemia

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 13-20

  Riches, John C ^a   Ramsay, Alan G ^a   Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adoptive T cell therapies; CD40 ligand; Chimeric antigen receptor; Chronic lymphocytic leukemia; CLL; Gene therapy; Immune reconstitution; Immune suppression; Lenalidomide

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD40 LIGAND; CHLORAMBUCIL; FLUDARABINE; LENALIDOMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; RITUXIMAB; T LYMPHOCYTE RECEPTOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DRUG EFFICACY; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; REVIEW; TUMOR IMMUNITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANTINEOPLASTIC AGENTS; CD40 LIGAND; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84859261502     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0106-x     Document Type: Review

References (79)

1. Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocyticleukemia. Blood 2009, 114:3382-91. This important clinicaltrial highlights the challenges of successfully treating elderlypatients with CLL, emphasizing the need for novel noncytotoxic therapies for this disease.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-74. This phase 3 trial demonstrates the survival advantage of the addition of rituximab to fludarabineand cyclophosphamide, and underpins the current standard of care in CLL.
3. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8. (Pubitemid 35363648)
4. Catovsky D, Miliani E, Okos A, et al. Clinical significance of Tcells in chronic lymphocytic leukaemia. Lancet. 1974;2:751-2.
5. Platsoucas CD, Galinski M, Kempin S, et al. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. J Immunol. 1982;129:2305-12. (Pubitemid 12004414)
6. Herrmann F, Lochner A, Philippen H, et al. Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. Clin Exp Immunol. 1982;49:157-62. (Pubitemid 12085209)
7. Van den Hove LE, Vandenberghe P, Van Gool SW, et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res. 1998;22:175-84. (Pubitemid 28185348)
8. Velardi A, Prchal JT, Prasthofer EF, et al. Expression of NKlineage markers on peripheral blood lymphocytes with T-helper (Leu3+/T4+) phenotype in B cell chronic lymphocytic leukemia. Blood. 1985;65:149-55. (Pubitemid 15191051)
9. Rossi E, Matutes E, Morilla R, et al. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia. 1996;10:494-7. (Pubitemid 26128791)
10. Goolsby CL, Kuchnio M, Finn WG, et al. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry. 2000;42:188-95. (Pubitemid 30451719)
11. Rezvany MR, Jeddi-Tehrani M, Osterborg A, et al. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood. 1999;94:1063-9. (Pubitemid 29361839)
12. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chroniclymphocytic leukemia. J Immunol. 1997;158:1482-9. (Pubitemid 127469977)
13. Farace F, Orlanducci F, Dietrich PY, et al. T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol. 1994;153:4281-90. (Pubitemid 24322595)
14. Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMVspecific CD8+CD45RA+CD27-T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102:1057-63. (Pubitemid 36917804)
15. Pourgheysari B, Bruton R, Parry H, et al. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood. 2010;116:2968-74.
16. Akbar AN. The silent war against CMV in CLL. Blood. 2011;116:2869-70.
17. Mu X, Kay NE, Gosland MP, et al. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol. 1997;96:733-5. (Pubitemid 27115866)
18. Dancescu M, Rubio-Trujillo M, Biron G, et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med. 1992;176:1319-26.
19. Panayiotidis P, Ganeshaguru K, Jabbar SA, et al. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in Bchronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1993;85:439-45. (Pubitemid 23349043)
20. Kay NE, Han L, Bone N, et al. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol. 2001;112:760-7. (Pubitemid 32222850)
21. de Totero D, Reato G, Mauro F, et al. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chroniclymphocytic leukaemia. Br J Haematol. 1999;104:589-99. (Pubitemid 29119286)
22. Cerutti A, Kim EC, Shah S, et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat Immunol. 2001;2:150-6. (Pubitemid 33707935)
23. Foa R, Catovsky D, Brozovic M, et al. Clinical staging and immunological findings in chronic lymphocytic leukemia. Cancer. 1979;44:483-7. (Pubitemid 10220132)
24. Lauria F, Foa R, Mantovani V, et al. T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the Thelper subset. Br J Haematol. 1983;54:277-83. (Pubitemid 13097411)
25. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018-25. (Pubitemid 41291715)
26. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20:677-82.
27. D'Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cellnumber is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 2011;35:363-8.
28. Lindqvist CA, Christiansson LH, Simonsson B, et al. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology. 2010;133:371-6.
29. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocyticleukemia. Leuk Lymphoma. 2009;50:788-801.
30. Pallasch CP, Ulbrich S, Brinker R, et al. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res. 2009;33:460-4.
31. Gorgun G, Holderried TA, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115:1797-805. (Pubitemid 40979718)
32. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427-37. (Pubitemid 351949771)
33. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106:6250-5.
34. Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25:1452-8.
35. Cantwell M, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984-9.
36. Noelle RJ, Roy M, Shepherd DM, et al. A39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992;89:6550-4.
37. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/ BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925-35. (Pubitemid 23097382)
38. Dazzi F, D'Andrea E, Biasi G, et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol. 1995;75:26-32.
39. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia. 1997;11:572-80. (Pubitemid 27173945)
40. Kato K, Cantwell MJ, Sharma S, et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-41. (Pubitemid 28125292)
41. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96 (9):2917-24.
42. Wierda WG, Castro JE, Aguillon R, et al.: A phase I study of immune gene therapy for patients with CLL using a membranestable, humanized CD154. Leukemia 2010, 24:1893-900. This study of immune gene therapy with humanized CD154 demonstrated clinical responses and avoided the induction of an immune response seen with murine CD154.
43. Jak M, van Bochove GG, van Lier RA, et al. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. Leukemia. 2011;25:968-78.
44. Scielzo C, Apollonio B, Scarfo L, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia. 2011;25:1760-7.
45. Chen CI, Bergsagel PL, Paul H, et al.: Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2010, 29:1175-81. This study shows that single-agent lenalidomide has efficacy comparable to that of cytotoxic agents in treating previously untreated CLL.
46. Badoux XC, Keating MJ, Wen S, et al.: Lenalidomide as initialtherapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-98. This trial demonstrates the efficacy of lenalidomide in elderly patients with CLL, highlighting its potential as a treatment for this subgroup.
47. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519-25.
48. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2010;117:2127-35.
49. Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24:1972-5.
50. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomideanalogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-6. (Pubitemid 29295864)
51. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103:1787-90. (Pubitemid 38268973)
52. Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis. 2003;187:946-55. (Pubitemid 36337907)
53. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells through a PI3-kinase dependent pathway. Blood. 2009;115:2619-29.
54. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and functionof T regulatory cells. Cancer Immunol Immunother. 2009;58:1033-45.
55. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-6.
56. Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol. 2009;148:948-50.
57. Gribben JG, Hosing C, Maloney DG. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2011;17:S63-70.
58. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanomausing T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-7.
59. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-55. (Pubitemid 28406858)
60. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-9. (Pubitemid 44547756)
61. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9:704-16.
62. Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:956304.
63. Koehler P, Schmidt P, Hombach AA, et al. Engineered T cells forthe adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol. 2011;2012:595060.
64. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor associated antigen ROR1 can be targeted with T-cells modified to express a ROR1-specific chimeric antigen receptor. Blood.2010;116:4532-41.
65. Giordano Attianese GM, Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011;117:4736-45.
66. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116:3875-86.
67. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes costimulatedby CD80 and interleukin-15. Nat Med. 2003;9:279-86. (Pubitemid 36362782)
68. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20:70-5. (Pubitemid 34044918)
69. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of Blineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood. 2010;116:4099-102.
70. Kochenderfer JN, Dudley ME, Stetler-Stevenson M, et al.: A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T cells. Blood 2010, 116: Abstract 2865.
71. Brentjens R, Yeh R, Bernal Y, et al. Treatment of chronic lymphocyticleukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18:666-8.
72. Brentjens RJ, Riviere I, Park JH, et al.: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011.
73. Porter DL, Levine BL, Kalos M, et al.: Chimeric Antigen Receptor-Modified T cells in Chronic Lymphoid Leukemia. N Engl J Med 2011, 365:725-33. This case report provides a proof-ofconcept base for the use of chimeric antigen receptor-modified T cells in CLL.
74. Kalos M, Levine BL, Porter DL, et al.: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
75. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453-64.
76. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94:1266-73.
77. Urba WJ, Longo DL. Redirecting T cells. N Engl J Med. 2011;365:754-7.
78. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492-9.
79. Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009;33:1255-9.